Cognitive impairment in spinocerebellar ataxia type 12.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
04 2021
Historique:
received: 10 09 2020
revised: 25 02 2021
accepted: 09 03 2021
pubmed: 20 3 2021
medline: 6 1 2022
entrez: 19 3 2021
Statut: ppublish

Résumé

Cognitive impairment has now been recognised to be present in patients with several of spinocerebellar ataxias (SCAs). Cognitive impairment in patients with spinocerebellar ataxia type 12 has not been evaluated. To evaluate the cognitive impairment in patients diagnosed with spinocerebellar ataxia type 12 (SCA12). We conducted a cross sectional study and enrolled 30 (20 male and 10 female) genetically confirmed SCA12 patients and 30 healthy, age, gender and education matched individuals as controls. Cognitive domains were tested using a battery of validated neurocognitive tests. Mean age of patients was 51.6 ± 8.0 years and mean disease duration was 5.3 ± 3.0 years. Mean International Cooperative Ataxia Rating Scale (ICARS) score was 29.8 ± 12.5. SCA 12 patients scored significantly lower than controls in executive function and new learning ability. Other tested cognitive domains were also affected but did not reach statistical significance. Age, age at onset, severity of ataxia, disease duration and CAG repeat length did not correlate with cognitive impairment. Cognitive impairment is a part of the spectrum of SCA12 and is characterized by dysfunction in executive function and new learning ability even early in the course of disease.

Identifiants

pubmed: 33740701
pii: S1353-8020(21)00103-6
doi: 10.1016/j.parkreldis.2021.03.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-56

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Amit Agarwal (A)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Harsimarpreet Kaur (H)

Division of Clinical Neuropsychology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.

Ayush Agarwal (A)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Ashima Nehra (A)

Division of Clinical Neuropsychology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.

Shivam Pandey (S)

Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.

Ajay Garg (A)

Department of Neuroradiology, All India Institute of Medical Sciences, New Delhi, India.

Mohammed Faruq (M)

Institute of Genomics and Integrative Biology, Mall Road, New Delhi, India.

Roopa Rajan (R)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Garima Shukla (G)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Vinay Goyal (V)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Achal Kumar Srivastava (AK)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: achalsrivastava@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH